

**North of Tyne, Gateshead and North Cumbria
Area Prescribing Committee**
www.northoftyneapc.nhs.uk
Tuesday 11th October 2022 12:30 pm

AGENDA

1.	Apologies for absence	
2.	Declarations of interest	
3.	Appeals against previous decisions: None	
4.	Minutes from the meeting 05/07/22 Decision summary from 05/07/22	Enc.1. Enc.2.
5.	Matters arising not on the agenda	
6.	APC Action log <ul style="list-style-type: none"> • June update 	Enc.3.
7.	Report from the Formulary sub-group <ul style="list-style-type: none"> • Draft minutes from meeting held on 8/9/22 • Draft decision summary from meeting held on 8/9/22 	Enc.4. Enc.5.t/f
8.	Report from the Medicines Guidelines and Use Group <ul style="list-style-type: none"> • Draft minutes from meeting held on 5/9/22 • Guidance/documents for approval: <ul style="list-style-type: none"> ○ NENC ICS recurrent UTI guidance ○ NENC ICS recurrent UTI summary flowchart ○ HCQ RMOC ○ ED guideline ○ Urology guideline ○ Gender dysphoria ○ Antipsychotic leaflet • Guidance to retire: <ul style="list-style-type: none"> ○ Branded prescribing • Guidance to extend: <ul style="list-style-type: none"> ○ IMD guideline; request to extend to March 2023 	Enc.6. Enc.7. Enc.8. Enc.9. Enc.10. Enc.11. Enc.12. Enc.13.
9.	Opiate/pain management sub-group <ul style="list-style-type: none"> • Notes from meeting on 7/7/22 • Quarter 1 data 	Enc.14. Enc.15.
10.	NENC ICS <ul style="list-style-type: none"> • NENC Medicines Committee draft terms of reference • NENC MO Subcommittee (NTAG) Interim TOR • Minutes from formulary merging meeting 	Enc.16. Enc.17. Enc.18.
11.	Northern (NHS) Treatment Advisory Group (NTAG). http://ntag.nhs.uk/ <ul style="list-style-type: none"> • Draft minutes from meeting of 19/7/2022 • Approval of NEELI V 2022.2 	Enc.19. Enc.20.

12.	<p>RMOCs</p> <ul style="list-style-type: none"> • Hydroxychloroquine and chloroquine retinopathy monitoring Regional Medicines Optimisation Committees practical recommendations for safe ophthalmology monitoring of patients who are receiving long term hydroxychloroquine or chloroquine. • Shared care protocols update. 18 shared care protocols have now been published on the NHSE website at https://www.england.nhs.uk/medicines-2/regional-medicines-optimisation-committees-advice/shared-care-protocols/ • Survey on the future role of RMOC 	Email 8/9/22
13.	<p>NICE HSTs and Technology Appraisals published since last meeting:</p> <ul style="list-style-type: none"> • HST21 Setmelanotide for treating obesity caused by LEPR or POMC deficiency • MTG71 Faecal microbiota transplant for recurrent Clostridioides difficile infection • TA803 Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs • TA804 Teduglutide for treating short bowel syndrome • TA805 Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides • TA806: Belimumab for treating lupus nephritis (terminated appraisal) • TA807 Roxadustat for treating symptomatic anaemia in chronic kidney disease • TA808 Fenfluramine for treating seizures associated with Dravet syndrome • TA809 Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease • TA810 Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence • TA811 Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) • TA812 Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer – NEGATIVE APPRAISAL • TA813 Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors • TA814 Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis • TA815 Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs • TA816 Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer • TA817 Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence • TA818 Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma • TA819 Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies • TA820 Brolucizumab for treating diabetic macular oedema • TA821 Avalglucosidase alfa for treating Pompe disease • TA824 Dexamethasone intravitreal implant for treating diabetic macular oedema 	

14.	<p>NHS England</p> <ul style="list-style-type: none"> • Specialised Services circulars: <ul style="list-style-type: none"> ○ SSC2400- NICE Technology Appraisal Final Appraisal Determination: asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors ○ SSC2401-Palivizumab passive immunisation against Respiratory Syncytial Virus (RSV) in at-risk infants (2022/23 Season) ○ SSC2402-NICE Technology Appraisal Final Appraisal Determination: nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence ○ SSC2411: Specialised Commissioning update -NICE notification letter Jul-Oct ○ SSC2412- HST20 Selumetinib NICE notification letter and Appendix A ○ SSC2413- EAMS Voxelotor update letter to trusts ○ SSC2414: NICE Technology Appraisal Consultation Document: lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma ○ SSC2415- NICE Technology Appraisal Final Appraisal Determination: atezolizumab for adjuvant treatment of resected non-small-cell lung cancer ○ SSC2418- Specialised Commissioning Update Sept 22 ○ SSC2418 – Table One ○ SSC2419- NHS England update on selected providers of Inherited White Matter Disorders Diagnostic and Management Service (IWMD) (All Ages) ○ SSC2420- NICE Technology Appraisal Final Appraisal Determination: oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy 	Enc.21.
15.	<p>Chairman's action Approval of Eloine® and Estradot® patches on FSC chair's advice - formulary updated</p>	
16.	Any other business	
17.	<p>Date, time and venue of next meeting: 10/1/2023 12.30-3pm Microsoft teams</p>	